The potential to longitudinally monitor cytotoxic-induced cell death with 18F-labeled Annexin V has been shown, although the small magnitude of changes in tracer uptake post-therapy demonstrated despite large reductions in tumour size [29], and the high non-specific binding of Annexin V to viable tumour cells [30] may further limit its clinical utility. The gene discussed is ANXA5; the disease is neoplasm.